arXiv:2606. 19245v1 Announce Type: new Abstract: Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions.
arXiv:2606. 00555v1 Announce Type: new Abstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together.
arXiv:2608. 06961v1 Announce Type: new Abstract: Early-stage molecular design is an iterative process, not just a task of generating molecules.
PMO-Dock introduces a standardized benchmark for docking‑based molecular optimization, comprising 25 tasks that span hit generation, lead optimization, and a specificity task that rewards strong on‑target binding while penalizing off‑target interactions. The protocol separates model development from final evaluation, using validation tasks for hyperparameter tuning and held‑out test tasks evaluated under a strict oracle budget to mimic realistic drug‑discovery constraints. Four diverse methods—Saturn, GenMol, Genetic‑guided GFlowNet, and ChemLlama—were benchmarked, revealing no single method dominates across all tasks and highlighting limited hyperparameter transferability, which underscores the need for method‑dependent selection strategies.
arXiv:2607. 08404v1 Announce Type: cross Abstract: Current computational approaches for drug design typically focus on generating molecules conditioned on specific targets or general molecular properties, often neglecting the influence of disease context on target behavior and therapeutic outcomes.
The paper introduces MAGI, an open modular agent that orchestrates molecular‑design tools by setting objectives, launching optimization, interpreting structure–activity relationships, and adjusting strategy. In nine retrospective lead‑optimization campaigns from three pharmaceutical companies, MAGI produced valid molecules via either direct LLM generation or delegation to REINVENT 4; LLM proposals stayed closer to local chemistry and achieved comparable or higher activity with fewer operations, while REINVENT explored broader chemical space. The success of a campaign depended on the accuracy of predictive models rather than the generation route, and a blinded evaluation showed chemists could not distinguish MAGI’s outputs from expert‑generated compounds, though the SAR reasoning was deemed plausible yet incomplete. The study positions MAGI as a coordination layer that can be plugged into existing workflows, but notes that the current ceiling for real projects is set by scorer applicability rather than tool orchestration.
arXiv:2610.19920v1 Announce Type: new Abstract: Molecular design is often formulated as an optimization problem over existing molecular spaces. However, molecular optimization and the discovery of st...
arXiv:2609.21859v1 Announce Type: new Abstract: Nearly 90% of drugs entering clinical development ultimately fail, despite billions of dollars in investment. Pharmaceutical companies therefore rely o...
arXiv:2607. 13155v1 Announce Type: new Abstract: Generative molecular models can support early drug discovery by proposing new candidate compounds de novo.
Molecular design is often formulated as an optimization problem over existing molecular spaces. However, molecular optimization and the discovery of structurally distinct replacement molecules represe...
arXiv:2511.20510v3 Announce Type: replace Abstract: Molecule generation from extremely limited training data is a key challenge in drug discovery. Existing fragment-based methods are more suitable th...
arXiv:2408. 13378v5 Announce Type: replace Abstract: Workflows in drug-target interaction (DTI) assessment require integrating heterogeneous data from predictive models, curated resources, and observations from experimental literature.